Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leigh MacConell

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Diabetes Care|July 12, 2014
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetesMichaela Diamant, Michael A Nauck, Rimma Shaginian, et al.
Contemporary Clinical Trials|July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitisVlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|May 24, 2023
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populationsRotonya M Carr, Yun Li, Lillian Chau, et al.
The Lancet. Gastroenterology & Hepatology|March 30, 2019
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension studyMichael Trauner, Frederik Nevens, Mitchell L Shiffman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 13, 2019
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patientsPaul J Pockros, Michael Fuchs, Bradley Freilich, et al.
NEJM Evidence|June 7, 2026
HTD1801 in Combination with Metformin for Type 2 DiabetesLinong Ji, Zhifeng Cheng, Jianhua Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2019
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary CholangitisChristopher L Bowlus, Paul J Pockros, Andreas E Kremer, et al.
Journal of Hepatology|March 14, 2020
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitisKris V Kowdley, Raj Vuppalanchi, Cynthia Levy, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Liver International : Official Journal of the International Association for the Study of the Liver|January 31, 2024
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASHNaim Alkhouri, Carl LaCerte, Jeffrey Edwards, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Diabetes Care|July 12, 2014
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetesMichaela Diamant, Michael A Nauck, Rimma Shaginian, et al.
Contemporary Clinical Trials|July 2, 2019
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitisVlad Ratziu, Arun J Sanyal, Rohit Loomba, et al.
Hepatology (Baltimore, Md.)|May 24, 2023
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populationsRotonya M Carr, Yun Li, Lillian Chau, et al.
The Lancet. Gastroenterology & Hepatology|March 30, 2019
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension studyMichael Trauner, Frederik Nevens, Mitchell L Shiffman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 13, 2019
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patientsPaul J Pockros, Michael Fuchs, Bradley Freilich, et al.
NEJM Evidence|June 7, 2026
HTD1801 in Combination with Metformin for Type 2 DiabetesLinong Ji, Zhifeng Cheng, Jianhua Ma, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2019
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary CholangitisChristopher L Bowlus, Paul J Pockros, Andreas E Kremer, et al.
Journal of Hepatology|March 14, 2020
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitisKris V Kowdley, Raj Vuppalanchi, Cynthia Levy, et al.
Pageof 4